David Reboussin to Coronary Artery Disease
This is a "connection" page, showing publications David Reboussin has written about Coronary Artery Disease.
Connection Strength
0.270
-
Yeboah J, Klein K, Brosnihan B, Reboussin D, Herrington DM. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Menopause. 2008 Nov-Dec; 15(6):1060-4.
Score: 0.066
-
Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath KV, Cupples LA, White C, Demissie S, Schaefer EJ, Asztalos BF. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):575-9.
Score: 0.062
-
Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J. 2007 Mar; 153(3):439-44.
Score: 0.059
-
Sherman AM, Shumaker SA, Kancler C, Zheng B, Reboussin DM, Legault C, Herrington DM. Baseline health-related quality of life in postmenopausal women with coronary heart disease: the Estrogen Replacement and Atherosclerosis (ERA) trial. J Womens Health (Larchmt). 2003 May; 12(4):351-62.
Score: 0.045
-
Folmar S, Oates-Williams F, Sharp P, Reboussin D, Smith J, Cheshire K, Macer J, Potvin Klein K, Herrington D. Recruitment of participants for the Estrogen Replacement and Atherosclerosis (ERA) trial. a comparison of costs, yields, and participant characteristics from community- and hospital-based recruitment strategies. Control Clin Trials. 2001 Feb; 22(1):13-25.
Score: 0.038